Dyne Therapeutics, Inc. (DYN)
Automate Your Wheel Strategy on DYN
With Tiblio's Option Bot, you can configure your own wheel strategy including DYN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DYN
- Rev/Share 0.0
- Book/Share 6.0865
- PB 2.011
- Debt/Equity 0.0349
- CurrentRatio 20.3501
- ROIC -0.5736
- MktCap 1391284080.0
- FreeCF/Share -2.9377
- PFCF -4.3088
- PE -3.6644
- Debt/Assets 0.0324
- DivYield 0
- ROE -0.5283
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DYN | Evercore ISI | -- | Outperform | -- | $46 | May 29, 2025 |
| Initiation | DYN | BMO Capital Markets | -- | Outperform | -- | $50 | March 12, 2025 |
| Initiation | DYN | Scotiabank | -- | Sector Outperform | -- | $50 | March 7, 2025 |
| Initiation | DYN | Robert W. Baird | -- | Outperform | -- | $46 | Dec. 13, 2024 |
News
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes -
Read More
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Published: March 13, 2025 by: Seeking Alpha
Sentiment: Positive
Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1, expected in the 1st half of 2026. With positive data released from phase 1/2 ACHIEVE study, plus FDA allowing splicing correction as a surrogate biomarker, it sets up a possible Accelerated Approval filing of DYNE-101 in 2026.
Read More
About Dyne Therapeutics, Inc. (DYN)
- IPO Date 2020-09-17
- Website https://www.dyne-tx.com
- Industry Biotechnology
- CEO Mr. John G. Cox M.B.A.
- Employees 192